ARVN

Arvinas (ARVN)

Arvinas Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ARVN

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/10	05 : 42	GlobeNewswire Inc.	Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress	NASDAQ:ARVN	Arvinas Inc
2024/05/08	05 : 13	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ARVN	Arvinas Inc
2024/05/07	20 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ARVN	Arvinas Inc
2024/05/07	20 : 00	GlobeNewswire Inc.	Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update	NASDAQ:ARVN	Arvinas Inc
2024/05/02	20 : 00	GlobeNewswire Inc.	Arvinas to Present at Upcoming Investor Conferences	NASDAQ:ARVN	Arvinas Inc
2024/04/25	05 : 30	GlobeNewswire Inc.	Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer	NASDAQ:ARVN	Arvinas Inc
2024/04/11	20 : 00	GlobeNewswire Inc.	Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer	NASDAQ:ARVN	Arvinas Inc
2024/03/19	05 : 40	GlobeNewswire Inc.	Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer	NASDAQ:ARVN	Arvinas Inc
2024/03/04	21 : 00	GlobeNewswire Inc.	Arvinas to Participate in Upcoming Investor Conferences	NASDAQ:ARVN	Arvinas Inc
2024/02/28	08 : 35	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARVN	Arvinas Inc
2024/02/28	08 : 34	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARVN	Arvinas Inc
2024/02/28	08 : 33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARVN	Arvinas Inc
2024/02/28	08 : 33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARVN	Arvinas Inc
2024/02/28	06 : 46	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:ARVN	Arvinas Inc
2024/02/27	21 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ARVN	Arvinas Inc
2024/02/27	21 : 00	GlobeNewswire Inc.	Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	NASDAQ:ARVN	Arvinas Inc
2024/02/21	06 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ARVN	Arvinas Inc
2024/02/21	06 : 05	GlobeNewswire Inc.	Arvinas Announces Chief Financial Officer Transition	NASDAQ:ARVN	Arvinas Inc
2024/02/20	21 : 00	GlobeNewswire Inc.	Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease	NASDAQ:ARVN	Arvinas Inc
2024/02/14	22 : 00	GlobeNewswire Inc.	Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer	NASDAQ:ARVN	Arvinas Inc
2024/02/14	10 : 14	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ARVN	Arvinas Inc
2024/02/06	20 : 45	GlobeNewswire Inc.	Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer	NASDAQ:ARVN	Arvinas Inc
2024/02/02	06 : 30	GlobeNewswire Inc.	Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference	NASDAQ:ARVN	Arvinas Inc
2024/01/17	07 : 01	GlobeNewswire Inc.	Arvinas Appoints Jared Freedberg as General Counsel	NASDAQ:ARVN	Arvinas Inc
2024/01/17	06 : 03	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ARVN	Arvinas Inc
2024/01/09	06 : 39	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARVN	Arvinas Inc
2024/01/08	21 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ARVN	Arvinas Inc
2023/12/08	23 : 16	Edgar (US Regulatory)	Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers	NASDAQ:ARVN	Arvinas Inc
2023/12/06	21 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ARVN	Arvinas Inc
2023/12/06	12 : 52	GlobeNewswire Inc.	Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program	NASDAQ:ARVN	Arvinas Inc